File No. 99-16C1 Serial No. FORM PTO 1449 U.S. DEPARTMENT OF COMMERCE 10/659.684 (REV 2-32) PATENT AND TRADEMARK OFFICE Applicant(s): INFORMATION DISCLOSURE STATEMENT BY APPLICANT Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard (Use several sheets if necessary) D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond Group: 1644 1647 JUL 1 4 2005 Filing Date: September 10, 2003 U.S. PATENT DOCUMENTS EXAMINER DOCUMENT FILING DATE IF DATE NAME CLASS SUBCLASS APPROPRIATE INITIAL NUMBER Nelson et al. 10/456,262 06-06-03 11/285,970 Yee A2 11/23/05 Novak et al. **A3** 11/346,580 02-02-06 2004-0009150 01-15-04 Nelson et al. A4 2004-0260065 Novak et al. 12/23/04 **A5** 2005-0095223 05-05-05 Sivakumar et al. A6 11/03/05 Preșnell et al. 2005-0244930 A7 2005-0265966 12-01-05 Kindsvogel et al. A8 2006-0134754 06/22/06 Chan et al. **A9** 6,307,024 10/23/01 Parrish et al. D A10 All 6,605,272 08/12/03 Dillon et al. A12 6,686,178 02-03-04 Dillon et al. 08/16/05 Presnell et al. A13 | 6,929,932 FOREIGN PATENT DOCUMENTS FILING DATE IF EXAMINER DOCUMENT INTTIAL NUMBER DATE COUNTRY CLASS SUBCLASS APPROPRIATE 03/103589 12/18/03 wo A14 A15 04/032857 04/22/04 wo wo A16 05/037306 04/28/05 wo 12/02/99 A17 99/61617 A18 04/112703 12/29/04 wo OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.) Hill et al., "Cytokines: promoters and dampeners of autoimmunity," Current Opinion in Immunology, Current AI9 JS Biology LTD 14(6):791-797, 2002. Clegg et al., "Therapeutic Opportunities for IL-21," European Cytokine Network vol. 14, no. Supplement 3, A20 A21 Nelson, et al., "Interleukin 21 has anti-tumor activity in animal models without the toxicity of IL-2," Procedures of the American Association for Cancer Research Annual Meeting, vol. 44, July 2003. A22 Funaro et al., "Monoclonal antibodies and therapy of human cancers," Biotechnology Advances, Elsevier Publishing Barking, GB vol. 18 no. 5, 2000. Examiner Date considered 10/02/2006 /Jegatheesan Seharaseyon/ EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to

6/3/8

applicant.